Upping the antedrug

Is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator?

E. H. Kaufman, David Jacoby

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In this issue of British Journal of Pharmacology, Biffen and colleagues present a novel Toll-like receptor 7 (TLR7) antedrug to treat allergic disease that is rapidly metabolized in the lung to limit side effects due to systemic exposure. Asthma is characterized as an allergic disease of the lung, and TLR7 agonists are proposed to ameliorate allergic inflammation in the lung, a characteristic of prophylactic medications. We have previously shown that TLR7 agonists of multiple structural classes are acute bronchodilators, characteristic of rescue medication for asthma attacks. It will be interesting to determine whether the bronchodilating effect extends to the novel class of TLR7 agonists described here for a prophylactic and rescue therapy in one drug. Combined with the antedrug approach, this would further limit side effects improving on current combination therapies.

Original languageEnglish (US)
Pages (from-to)569-572
Number of pages4
JournalBritish Journal of Pharmacology
Volume166
Issue number2
DOIs
StatePublished - May 2012

Fingerprint

Toll-Like Receptor 7
Bronchodilator Agents
Anti-Inflammatory Agents
Asthma
Lung Diseases
Pneumonia
Pharmacology
Lung
Therapeutics
Pharmaceutical Preparations

Keywords

  • allergy
  • antedrug
  • asthma
  • bronchodilator
  • immunomodulator
  • inflammation
  • Toll-like receptor 7

ASJC Scopus subject areas

  • Pharmacology

Cite this

Upping the antedrug : Is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator? / Kaufman, E. H.; Jacoby, David.

In: British Journal of Pharmacology, Vol. 166, No. 2, 05.2012, p. 569-572.

Research output: Contribution to journalArticle

@article{f3711f276e8944d39dd0e83fd8207206,
title = "Upping the antedrug: Is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator?",
abstract = "In this issue of British Journal of Pharmacology, Biffen and colleagues present a novel Toll-like receptor 7 (TLR7) antedrug to treat allergic disease that is rapidly metabolized in the lung to limit side effects due to systemic exposure. Asthma is characterized as an allergic disease of the lung, and TLR7 agonists are proposed to ameliorate allergic inflammation in the lung, a characteristic of prophylactic medications. We have previously shown that TLR7 agonists of multiple structural classes are acute bronchodilators, characteristic of rescue medication for asthma attacks. It will be interesting to determine whether the bronchodilating effect extends to the novel class of TLR7 agonists described here for a prophylactic and rescue therapy in one drug. Combined with the antedrug approach, this would further limit side effects improving on current combination therapies.",
keywords = "allergy, antedrug, asthma, bronchodilator, immunomodulator, inflammation, Toll-like receptor 7",
author = "Kaufman, {E. H.} and David Jacoby",
year = "2012",
month = "5",
doi = "10.1111/j.1476-5381.2011.01758.x",
language = "English (US)",
volume = "166",
pages = "569--572",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Upping the antedrug

T2 - Is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator?

AU - Kaufman, E. H.

AU - Jacoby, David

PY - 2012/5

Y1 - 2012/5

N2 - In this issue of British Journal of Pharmacology, Biffen and colleagues present a novel Toll-like receptor 7 (TLR7) antedrug to treat allergic disease that is rapidly metabolized in the lung to limit side effects due to systemic exposure. Asthma is characterized as an allergic disease of the lung, and TLR7 agonists are proposed to ameliorate allergic inflammation in the lung, a characteristic of prophylactic medications. We have previously shown that TLR7 agonists of multiple structural classes are acute bronchodilators, characteristic of rescue medication for asthma attacks. It will be interesting to determine whether the bronchodilating effect extends to the novel class of TLR7 agonists described here for a prophylactic and rescue therapy in one drug. Combined with the antedrug approach, this would further limit side effects improving on current combination therapies.

AB - In this issue of British Journal of Pharmacology, Biffen and colleagues present a novel Toll-like receptor 7 (TLR7) antedrug to treat allergic disease that is rapidly metabolized in the lung to limit side effects due to systemic exposure. Asthma is characterized as an allergic disease of the lung, and TLR7 agonists are proposed to ameliorate allergic inflammation in the lung, a characteristic of prophylactic medications. We have previously shown that TLR7 agonists of multiple structural classes are acute bronchodilators, characteristic of rescue medication for asthma attacks. It will be interesting to determine whether the bronchodilating effect extends to the novel class of TLR7 agonists described here for a prophylactic and rescue therapy in one drug. Combined with the antedrug approach, this would further limit side effects improving on current combination therapies.

KW - allergy

KW - antedrug

KW - asthma

KW - bronchodilator

KW - immunomodulator

KW - inflammation

KW - Toll-like receptor 7

UR - http://www.scopus.com/inward/record.url?scp=84859904767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859904767&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01758.x

DO - 10.1111/j.1476-5381.2011.01758.x

M3 - Article

VL - 166

SP - 569

EP - 572

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -